Hepacure

Company Overview

Snapshot

Founded in July 2024, Hepacure operates with 1–10 employees. The company has secured funding across one round from one investor, NGT HealthCare II, for its peptide therapy targeting fatty liver diseases.

Business overview

Hepacure Pharma is developing a novel peptide therapy focused on treating fatty liver diseases, specifically non-alcoholic fatty liver disease (NAFLD) and its advanced forms like non-alcoholic steatohepatitis (NASH). The core technology centers on a peptide named Luji, which aims to mitigate fibrosis and reactivate immune responses in the liver by blocking key proteins in the fibrosis pathway and enabling natural killer (NK) cells to target hepatic stellate cells (HSCs). This therapy, designed for once-weekly injections, targets early-stage fibrosis to prevent further liver deterioration in NAFLD patients. Hepacure operates within the Health Tech & Life Sciences sector, with a focus on Pharmaceuticals and Drugs Discovery & Development.

Company Intelligence Q&A

What is Hepacure's primary focus?

Hepacure is developing a novel peptide therapy to target fibrosis in fatty liver diseases, including non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH).

What is the key mechanism of Hepacure's therapy?

Hepacure's therapy utilizes a peptide called Luji, which is designed to block key proteins in the fibrosis pathway and reactivate natural killer (NK) cells to target hepatic stellate cells (HSCs), thereby modulating the NLGN4-Nrx1β protein interaction to prevent fibrosis advancement.

When was Hepacure founded?

Hepacure was founded in July 2024.

What is the current development stage of Hepacure's product?

Hepacure's product is currently in the R&D stage, with preclinical fibrosis mouse models demonstrating potential in slowing fibrosis progression and reducing liver inflammation.